CPRX
Catalyst Pharmaceuticals, Inc. NASDAQ Listed Nov 8, 2006$31.38
-0.06%
vs $31.40
Mkt Cap $4.0B
52w Low $19.13
99.8% of range
52w High $31.40
50d MA $29.70
200d MA $24.43
P/E (TTM)
18.7x
EV/EBITDA
10.2x
P/B
4.0x
Debt/Equity
0.0x
ROE
22.5%
P/FCF
19.1x
RSI (14)
75.90
ATR (14)
$0.04
Beta
0.66
50d MA
$29.70
200d MA
$24.43
Avg Volume
2.7M
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
355 Alhambra Circle · Coral Gables, FL 33134 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | AMC | 0.42 | 0.68 | +61.9% | 24.86 | -1.5% | +0.1% | -7.2% | +3.5% | +0.2% | +3.2% | — |
| Nov 5, 2025 | AMC | 0.51 | 0.68 | +33.3% | 21.38 | +5.6% | -1.8% | +1.9% | +0.8% | +7.1% | -1.4% | — |
| Aug 6, 2025 | AMC | 0.58 | 0.68 | +17.2% | 21.79 | -0.5% | -9.9% | +1.1% | -0.9% | +3.4% | -0.7% | — |
| May 7, 2025 | AMC | 0.53 | 0.68 | +28.3% | 23.46 | -1.2% | -3.0% | +2.7% | +2.0% | -0.8% | -1.1% | — |
| Feb 26, 2025 | AMC | 0.32 | 0.70 | +118.8% | 20.58 | +8.5% | +5.2% | +5.7% | -2.5% | -1.0% | -1.0% | — |
| Nov 6, 2024 | AMC | 0.49 | 0.57 | +16.3% | 22.71 | +6.6% | +2.4% | +2.9% | -2.0% | -1.7% | -1.0% | — |
| Aug 7, 2024 | AMC | 0.42 | 0.56 | +33.3% | 16.23 | +7.8% | +12.8% | +1.0% | +4.4% | +1.5% | -1.8% | — |
| May 8, 2024 | AMC | 0.34 | 0.38 | +11.8% | 14.72 | +1.0% | +6.3% | +1.9% | +1.8% | +1.7% | +1.0% | — |
| Feb 28, 2024 | AMC | 0.48 | 0.53 | +10.4% | 14.56 | +11.9% | +10.1% | +6.1% | -1.9% | -2.5% | -2.5% | — |
| Nov 8, 2023 | AMC | -0.24 | -0.24 | +0.0% | 12.54 | +6.8% | -1.8% | +4.3% | -1.7% | +5.9% | +2.0% | — |
| Aug 9, 2023 | AMC | 0.25 | 0.33 | +32.0% | 14.12 | +6.4% | +6.4% | -0.9% | -0.1% | +0.8% | -1.6% | — |
| May 10, 2023 | AMC | 0.32 | 0.26 | -18.8% | 17.51 | +0.0% | -19.2% | -4.9% | -2.3% | -4.8% | +0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3 | Citigroup | Maintains | Buy → Buy | — | $23.88 | $23.88 | +0.0% | +0.2% | +3.2% | -1.5% | -0.3% | +2.3% |
| Nov 7 | Citigroup | Maintains | Buy → Buy | — | $20.99 | $21.27 | +1.3% | +1.9% | +0.8% | +7.1% | -1.4% | +1.1% |
| Mar 3 | Baird | Maintains | Outperform → Outperform | — | $22.89 | $22.89 | +0.0% | -2.5% | -1.0% | -1.0% | -1.0% | +1.3% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.66 | $21.93 | +1.2% | +5.7% | -2.5% | -1.0% | -1.0% | -1.0% |
| Feb 27 | Stephens & Co. | Maintains | Overweight → Overweight | — | $20.58 | $22.32 | +8.5% | +5.2% | +5.7% | -2.5% | -1.0% | -1.0% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.80 | $22.85 | +0.2% | -3.9% | +1.3% | -0.1% | +3.9% | -1.7% |
| Jan 9 | BofA Securities | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Nov 11 | Truist | Maintains | Buy → Buy | — | $23.93 | $24.10 | +0.7% | -2.0% | -1.7% | -1.0% | -4.9% | -5.0% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.25 | $23.50 | +1.1% | +2.9% | -2.0% | -1.7% | -1.0% | -4.9% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.48 | $18.83 | +1.9% | +4.4% | +1.5% | -1.8% | +3.5% | -0.2% |
| Aug 9 | Citigroup | Maintains | Buy → Buy | — | $18.30 | $18.45 | +0.8% | +1.0% | +4.4% | +1.5% | -1.8% | +3.5% |
| Aug 9 | Truist | Maintains | Buy → Buy | — | $18.30 | $18.45 | +0.8% | +1.0% | +4.4% | +1.5% | -1.8% | +3.5% |
| Jun 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $16.31 | $16.20 | -0.7% | -3.4% | -0.9% | +0.1% | -0.4% | -0.7% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.17 | $16.27 | +0.6% | +0.1% | -0.9% | +1.7% | -3.4% | -0.9% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.65 | $15.83 | +1.2% | +1.9% | +1.8% | +1.7% | +1.0% | -1.6% |
| Mar 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $15.75 | $15.90 | +1.0% | +3.3% | -2.0% | -1.3% | -3.0% | +1.5% |
| Mar 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $16.62 | $16.60 | -0.1% | -5.4% | +0.8% | -0.7% | +3.3% | -2.0% |
| Mar 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $16.62 | $17.02 | +2.4% | -2.6% | -0.7% | +0.1% | +1.9% | +3.2% |
| Mar 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $16.03 | $16.20 | +1.1% | +6.1% | -1.9% | -2.5% | -2.5% | +4.9% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.03 | $16.20 | +1.1% | +6.1% | -1.9% | -2.5% | -2.5% | +4.9% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $14.60 | $14.59 | -0.1% | -1.2% | -1.9% | -2.1% | +2.8% | -0.2% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.02 | $15.08 | +0.4% | -0.9% | -0.1% | +0.8% | -1.6% | -3.4% |
| Aug 11 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $15.02 | $15.08 | +0.4% | -0.9% | -0.1% | +0.8% | -1.6% | -3.4% |
| Jul 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.68 | $13.73 | +0.4% | -0.1% | -0.9% | -1.0% | -0.7% | +0.2% |
| Jun 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $12.62 | $12.85 | +1.8% | +5.0% | -0.9% | +0.2% | -1.9% | +1.8% |
| Jun 21 | Truist | Maintains | Buy → Buy | — | $12.62 | $12.85 | +1.8% | +5.0% | -0.9% | +0.2% | -1.9% | +1.8% |
| Jun 20 | Truist | Maintains | Buy → Buy | — | $12.20 | $12.14 | -0.5% | +3.4% | +5.0% | -0.9% | +0.2% | -1.9% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.15 | $14.16 | +0.1% | -4.9% | -2.3% | -4.8% | +0.2% | -2.6% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.92 | $15.96 | +0.3% | +3.0% | +0.8% | -1.9% | -1.2% | +0.6% |
| Jan 19 | Truist | Maintains | Buy → Buy | — | $20.43 | $20.31 | -0.6% | -0.8% | +2.6% | -29.0% | +9.2% | +3.8% |
| Dec 21 | Truist | Maintains | Buy → Buy | — | $18.60 | $18.92 | +1.7% | +4.8% | -0.8% | -1.8% | -2.2% | -2.5% |
| Dec 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.60 | $18.92 | +1.7% | +4.8% | -0.8% | -1.8% | -2.2% | -2.5% |
| Dec 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.41 | $16.80 | +2.4% | +13.3% | +4.8% | -0.8% | -1.8% | -2.2% |
| Aug 24 | Roth Capital | Downgrade | Buy → Neutral | — | $14.91 | $14.47 | -3.0% | -6.3% | +2.6% | -2.2% | +0.7% | -1.8% |
| Aug 11 | Truist | Maintains | Buy → Buy | — | $13.13 | $13.10 | -0.2% | +1.8% | +4.0% | +2.4% | -1.8% | -1.7% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.13 | $13.10 | -0.2% | +1.8% | +4.0% | +2.4% | -1.8% | -1.7% |
| Feb 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.54 | $6.56 | +0.3% | +6.9% | +5.2% | +0.8% | +7.2% | -4.5% |
| Mar 18 | Roth Capital | Maintains | Buy → Buy | — | $4.23 | $4.24 | +0.2% | -0.5% | +3.8% | +7.3% | -0.4% | -8.1% |
| Aug 12 | Truist | Maintains | Buy → Buy | — | $3.34 | $3.45 | +3.3% | +0.6% | +1.5% | +1.8% | +6.3% | -1.4% |
| May 13 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $4.58 | $4.63 | +1.0% | -4.4% | -2.9% | +6.8% | +0.0% | -5.5% |
| Feb 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.77 | $4.89 | +2.5% | +0.0% | +7.5% | +0.2% | +1.2% | +0.2% |
| Dec 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.40 | $2.52 | +5.0% | +2.5% | -4.9% | +0.0% | +3.8% | -7.8% |
| Nov 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.13 | $2.98 | -4.8% | -11.5% | -8.5% | -5.9% | -3.6% | -3.0% |
| Sep 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.14 | $3.17 | +1.0% | +0.3% | +9.2% | +1.5% | +6.3% | +1.3% |
| Jul 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.20 | $3.46 | +8.1% | +2.2% | -1.2% | -1.9% | -2.8% | +0.0% |
| Oct 5 | Piper Sandler | Upgrade | Neutral → Overweight | — | $1.12 | $1.28 | +14.3% | +30.4% | -4.8% | -2.2% | -2.9% | -5.3% |
| Apr 26 | Piper Sandler | Downgrade | Overweight → Neutral | — | $1.24 | $0.55 | -55.6% | -49.2% | +0.0% | +0.8% | +7.1% | -2.5% |
| Jun 24 | MLV & Co. | Maintains | Buy → Buy | — | $3.99 | $4.31 | +8.0% | +3.5% | +4.4% | -1.2% | -8.2% | +5.6% |
| Feb 25 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $3.73 | $3.90 | +4.6% | -0.8% | +2.2% | -0.5% | +0.0% | -2.9% |
| Apr 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.06 | $2.17 | +5.3% | -4.9% | -2.0% | +5.7% | +1.5% | -1.0% |
No insider trades available.
8-K
Catalyst Pharmaceuticals, Inc. -- 8-K Filing
May 11
8-K
Catalyst Pharmaceuticals, Inc. -- 8-K Filing
Catalyst Pharmaceuticals' merger agreement provides cash consideration for in-the-money stock options while canceling out-of-the-money options, affecting shareholder and optionholder economics in the transaction.
May 7
8-K
Unknown — 8-K Filing
This appears to be a technical correction to a previously filed 8-K, suggesting no material business developments were omitted—investors should review the original filing for substantive information.
Mar 19
8-K
Unknown — 8-K Filing
I cannot write a meaningful analyst sentence about this filing because the 8-K summary provided contains only technical XBRL schema metadata rather than actual business event disclosures; an investor cannot assess stock impact without substantive filing content.
Mar 18
8-K
Catalyst Pharmaceutical Inc. -- 8-K Filing
Catalyst Pharmaceutical (CPRX) projects 2026 revenues of $615-645 million with promoted product revenue growth exceeding 20%, demonstrating confidence in its FIRDAPSE and AGAMREE drug franchises.
Feb 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 5,866,798 | $137M | Added | Dec 2025 |
| 2 | Vanguard Capital Management Llc | 5,122,666 | $127M | New | Mar 2026 |
| 3 | Deerfield Management Company, L.p. | 3,943,600 | $98M | Reduced | Mar 2026 |
| 4 | Bank Of America Corp /de/ | 3,036,546 | $75M | Added | Mar 2026 |
| 5 | Vanguard Portfolio Management Llc | 2,475,467 | $61M | New | Mar 2026 |
| 6 | Renaissance Technologies Llc | 2,347,477 | $58M | Reduced | Mar 2026 |
| 7 | Janus Henderson Group Plc | 1,998,875 | $50M | New | Mar 2026 |
| 8 | Boston Partners | 1,711,573 | $42M | Added | Mar 2026 |
| 9 | Northern Trust Corp | 1,237,752 | $31M | Added | Mar 2026 |
| 10 | Ubs Group Ag | 986,090 | $24M | Added | Mar 2026 |
| 11 | Arrowstreet Capital, Limited Partnership | 955,315 | $24M | Reduced | Mar 2026 |
| 12 | Raymond James Financial Inc | 889,940 | $22M | Added | Mar 2026 |
| 13 | Victory Capital Management Inc | 866,624 | $21M | Reduced | Mar 2026 |
| 14 | Susquehanna International Group, Llp | 852,820 | $21M | Added | Mar 2026 |
| 15 | Millennium Management | 766,991 | $19M | Reduced | Mar 2026 |
| 16 | Invesco Ltd. | 752,839 | $19M | Reduced | Mar 2026 |
| 17 | Systematic Financial Management Lp | 747,515 | $19M | Added | Mar 2026 |
| 18 | Bank Of New York Mellon Corp | 682,289 | $17M | Reduced | Mar 2026 |
| 19 | Principal Financial Group Inc | 683,678 | $16M | Added | Dec 2025 |
| 20 | Swedbank Ab | 616,132 | $15M | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$3.99B
Enterprise Value
$3.28B
P/E (TTM)
18.68x
Forward P/E
16.69x
PEG Ratio
0.50x
P/B
4.02x
P/S
6.78x
P/FCF
19.14x
EV/EBITDA
10.23x
Shares Out
127.3M
Financials (TTM)
Revenue
$589.0M
Net Income
$214.3M
EBITDA
$321.0M
Free Cash Flow
$208.6M
Op Cash Flow
$208.7M
EPS Basic
$1.75
EPS Diluted
$1.68
EPS Forward
$1.88
Gross Margin
85.2%
Op Margin
43.8%
Net Margin
36.4%
Balance Sheet
Total Assets
$1.11B
Total Liab.
$152.5M
Total Equity
$954.3M
Cash
$709.2M
LT Debt
$0
Book Value/Sh
$7.80
Debt/Equity
0.00x
Current Ratio
6.08
Quick Ratio
5.82
Returns & Growth
ROE
22.5%
ROA
19.4%
ROIC
20.3%
Rev Growth YoY
+19.8%
EPS Growth YoY
+26.8%
Price Returns
2W
+0.2%
1M
+11.0%
3M
+35.3%
6M
+33.4%
12M
+25.1%
Technicals
52W High
$31.40
52W Low
$19.13
50d MA
$29.70
200d MA
$24.43
RSI (14)
75.90
ATR (14)
$0.04
Beta
0.66
Avg Volume
2.7M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$33.00
High
$33.00
Low
$33.00
Median
$33.00
Data updated apr 25, 2026 2:55am
· Source: financialmodelingprep.com